AR105160A1 - Métodos de modulación de moléculas de vigilancia de adn citosólicas - Google Patents
Métodos de modulación de moléculas de vigilancia de adn citosólicasInfo
- Publication number
- AR105160A1 AR105160A1 ARP160101937A ARP160101937A AR105160A1 AR 105160 A1 AR105160 A1 AR 105160A1 AR P160101937 A ARP160101937 A AR P160101937A AR P160101937 A ARP160101937 A AR P160101937A AR 105160 A1 AR105160 A1 AR 105160A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- immunomodulatory composition
- administering
- nucleic acid
- acid sequence
- Prior art date
Links
- 230000001086 cytosolic effect Effects 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 7
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 4
- 230000037451 immune surveillance Effects 0.000 abstract 4
- 150000007523 nucleic acids Chemical group 0.000 abstract 4
- 230000028993 immune response Effects 0.000 abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 3
- 230000019491 signal transduction Effects 0.000 abstract 3
- 241000283690 Bos taurus Species 0.000 abstract 2
- 125000002091 cationic group Chemical group 0.000 abstract 2
- 230000015788 innate immune response Effects 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 239000003981 vehicle Substances 0.000 abstract 2
- 230000004584 weight gain Effects 0.000 abstract 2
- 235000019786 weight gain Nutrition 0.000 abstract 2
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Un método para generar una respuesta inmunológica en un sujeto receptor que comprende: a) administrar una composición inmunomoduladora al sujeto, en donde dicha composición inmunomoduladora comprende una secuencia de ácidos nucleicos que comprende por lo menos un motivo CpG inmunoestimulante, por lo menos un motivo CpG no inmunoestimulante y un liposoma catiónico; y b) activar receptores de vigilancia inmunológica, en donde los receptores de vigilancia inmunológica activan las vías de señalización involucradas en una respuesta inmunológica innata. Reivindicación 12: Un método para estimular una respuesta inmunológica en un sujeto que comprende: a) administrar al sujeto una composición inmunomoduladora, en donde dicha composición inmunomoduladora comprende una secuencia de ácidos nucleicos que presenta por lo menos 80% de homología de secuencia con la secuencia de la SEQ ID Nº 4 y un vehículo de administración liposómico; y, b) activar receptores de vigilancia inmunológica, en donde los receptores de vigilancia inmunológica activan las vías de señalización involucradas en una respuesta inmunológica innata. Reivindicación 22: Un método de modulación la vía de señalización STING para generar una respuesta inmunológica en un sujeto receptor que comprende: a) administrar una composición inmunomoduladora al sujeto, en donde dicha composición inmunomoduladora comprende una secuencia de ácidos nucleicos que comprende por lo menos un motivo CpG inmunoestimulante, por lo menos un motivo CpG no inmunoestimulante y un liposoma catiónico. Reivindicación 29: Un método para incrementar el aumento de peso del ganado diagnosticado con la enfermedad respiratoria bovina que comprende: administrar un agente antimicrobiano al sujeto en combinación con una composición inmunomoduladora que comprende una secuencia de ácidos nucleicos que presenta por lo menos un 80% de homología con la SEQ ID Nº 4 y un vehículo de administración lipídico, en donde dicha combinación incrementa el aumento de peso en el sujeto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185230P | 2015-06-26 | 2015-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105160A1 true AR105160A1 (es) | 2017-09-13 |
Family
ID=56235815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101937A AR105160A1 (es) | 2015-06-26 | 2016-06-28 | Métodos de modulación de moléculas de vigilancia de adn citosólicas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20190233825A1 (es) |
| EP (1) | EP3313376A2 (es) |
| JP (1) | JP2018518511A (es) |
| KR (1) | KR20180021874A (es) |
| CN (1) | CN108472255A (es) |
| AR (1) | AR105160A1 (es) |
| AU (1) | AU2016282879A1 (es) |
| BR (1) | BR112017028121A2 (es) |
| CA (1) | CA2990526A1 (es) |
| CL (1) | CL2017003373A1 (es) |
| CR (1) | CR20180003A (es) |
| DO (1) | DOP2017000313A (es) |
| HK (1) | HK1256128A1 (es) |
| IL (1) | IL256264A (es) |
| MX (1) | MX2017017141A (es) |
| PE (1) | PE20181208A1 (es) |
| PH (1) | PH12017502413A1 (es) |
| RU (1) | RU2018102915A (es) |
| SG (1) | SG10201913395VA (es) |
| TW (1) | TW201710509A (es) |
| UY (1) | UY36756A (es) |
| WO (1) | WO2016207314A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| TWI759317B (zh) | 2016-07-26 | 2022-04-01 | 德商拜耳動物保健有限公司 | 牛物種中增加的生育力 |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US155950A (en) * | 1874-10-13 | Improvement in hand-saws | ||
| EP1167377B2 (en) * | 1994-07-15 | 2012-08-08 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| DE69838294T2 (de) * | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| EP1326969B1 (en) * | 2000-09-25 | 2009-04-15 | Genetronics, Inc. | Improved system for regulation of transgene expression |
| AU2002953015A0 (en) * | 2002-12-02 | 2002-12-12 | Women's And Children's Hospital | Modified lacz gene |
| WO2005033265A2 (en) * | 2003-04-25 | 2005-04-14 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| AR044437A1 (es) * | 2003-05-29 | 2005-09-14 | Schering Plough Ltd | Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino |
| AU2005271247A1 (en) * | 2004-08-13 | 2006-02-16 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free DNA vaccines |
| EP2942391B1 (en) * | 2004-08-13 | 2018-05-23 | The Trustees Of The University Of Pennsylvania | Methods for constructing antibiotic resistance free vaccines |
| RU2570732C9 (ru) * | 2009-05-14 | 2016-09-10 | Байер Интеллектуэль Проперти Гмбх | Усиленный иммунный ответ у видов птиц |
| CA2822359C (en) * | 2010-12-22 | 2021-06-01 | Bayer Intellectual Property Gmbh | Enhanced immune response in bovine species |
| MX346596B (es) * | 2011-05-26 | 2017-03-23 | Intervet Int Bv | Oligodesoxinucleotidos inmunoestimuladores. |
| AR091569A1 (es) * | 2012-06-28 | 2015-02-11 | Intervet Int Bv | Receptores de tipo toll |
| RU2740492C2 (ru) * | 2014-02-28 | 2021-01-14 | Байер Энимэл Хельс ГмбХ | Иммуностимулирующие плазмиды |
-
2016
- 2016-06-23 CN CN201680049705.XA patent/CN108472255A/zh active Pending
- 2016-06-23 CA CA2990526A patent/CA2990526A1/en not_active Abandoned
- 2016-06-23 AU AU2016282879A patent/AU2016282879A1/en not_active Abandoned
- 2016-06-23 KR KR1020187002687A patent/KR20180021874A/ko unknown
- 2016-06-23 CR CR20180003A patent/CR20180003A/es unknown
- 2016-06-23 PE PE2017002822A patent/PE20181208A1/es unknown
- 2016-06-23 WO PCT/EP2016/064613 patent/WO2016207314A2/en active Application Filing
- 2016-06-23 EP EP16732278.3A patent/EP3313376A2/en not_active Withdrawn
- 2016-06-23 SG SG10201913395VA patent/SG10201913395VA/en unknown
- 2016-06-23 JP JP2017566839A patent/JP2018518511A/ja active Pending
- 2016-06-23 MX MX2017017141A patent/MX2017017141A/es unknown
- 2016-06-23 US US15/738,794 patent/US20190233825A1/en not_active Abandoned
- 2016-06-23 RU RU2018102915A patent/RU2018102915A/ru not_active Application Discontinuation
- 2016-06-23 BR BR112017028121A patent/BR112017028121A2/pt not_active IP Right Cessation
- 2016-06-24 TW TW105120099A patent/TW201710509A/zh unknown
- 2016-06-27 UY UY0001036756A patent/UY36756A/es not_active Application Discontinuation
- 2016-06-28 AR ARP160101937A patent/AR105160A1/es unknown
-
2017
- 2017-12-12 IL IL256264A patent/IL256264A/en unknown
- 2017-12-22 PH PH12017502413A patent/PH12017502413A1/en unknown
- 2017-12-26 DO DO2017000313A patent/DOP2017000313A/es unknown
- 2017-12-26 CL CL2017003373A patent/CL2017003373A1/es unknown
-
2018
- 2018-11-28 HK HK18115209.5A patent/HK1256128A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2017000313A (es) | 2018-02-28 |
| WO2016207314A2 (en) | 2016-12-29 |
| EP3313376A2 (en) | 2018-05-02 |
| WO2016207314A3 (en) | 2017-02-09 |
| UY36756A (es) | 2017-01-31 |
| RU2018102915A3 (es) | 2019-12-05 |
| CA2990526A1 (en) | 2016-12-29 |
| PH12017502413A1 (en) | 2018-06-25 |
| KR20180021874A (ko) | 2018-03-05 |
| PE20181208A1 (es) | 2018-07-23 |
| IL256264A (en) | 2018-02-28 |
| RU2018102915A (ru) | 2019-07-29 |
| SG10201913395VA (en) | 2020-03-30 |
| CR20180003A (es) | 2018-03-20 |
| BR112017028121A2 (pt) | 2018-09-04 |
| AU2016282879A1 (en) | 2018-01-18 |
| MX2017017141A (es) | 2018-03-09 |
| CN108472255A (zh) | 2018-08-31 |
| HK1256128A1 (zh) | 2019-09-13 |
| TW201710509A (zh) | 2017-03-16 |
| US20190233825A1 (en) | 2019-08-01 |
| CL2017003373A1 (es) | 2018-06-29 |
| JP2018518511A (ja) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008369A2 (pt) | ácidos ribonucleicos mensageiros para intensificar respostas imunes e métodos para uso dos mesmos | |
| ECSP17064523A (es) | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon" | |
| AR105160A1 (es) | Métodos de modulación de moléculas de vigilancia de adn citosólicas | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| PE20191152A1 (es) | Anticuerpos y polipeptidos dirigidos contra cd127 | |
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| PE20190335A1 (es) | Receptores de celulas t | |
| CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
| CY1121535T1 (el) | Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων | |
| EP4273160A3 (en) | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination | |
| BR112017014219A2 (pt) | vacinas à base de nanopartículas multivalentes | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| TR201908550T4 (tr) | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. | |
| AR105470A1 (es) | Métodos para inducir una respuesta inmune | |
| EA201791381A1 (ru) | Универсальная клетка т-киллер | |
| BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
| AR090469A1 (es) | Vacuna contra el virus sincicial respiratorio (rsv) | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| BR112016011866A2 (pt) | vetores de composições e métodos para induzir uma resposta imune potencializada usando vetores de poxvírus | |
| BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
| CL2020002561A1 (es) | Composiciones y métodos para el tratamiento de la distrofia macular | |
| UY36990A (es) | Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria |